Analysis of Inhaled Corticosteroid and Oral Theophylline Use Among Patients With Stable COPD from 1987 to 1995

• DOI: 10.1378/chest.115.3.703
• Publication Date: 2003-06-14T00:09:19Z
• Authors: Amy E. Van Andel; Colin Reisner; Shailendra S. Men...; Ted J. Witek
• Keywords: Male; Clinical Trials as Topic; Administration, Oral; Middle Aged; Bronchodilator Agents; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Theophylline; Administration, Inhalation; Humans; Female; Lung Diseases, Obstructive; Practice Patterns, Physicians'; Glucocorticoids; Aged; Retrospective Studies

To document temporal usage trends for commonly used respiratory medications in patients with COPD.We retrospectively evaluated baseline concomitant medications of 3,720 patients with COPD enrolled in 10 bronchodilator clinical trials from 1987 to 1995. The proportion of patients in each trial using inhaled corticosteroids, inhaled beta-adrenergics, inhaled anticholinergics, oral theophylline, and oral corticosteroids was analyzed using the Cochran-Armitage trend test.All patients had stable, moderate-to-severe COPD without evidence of asthma or atopy. Reversibility to beta3-agonists was not a requirement.The percentage of patients using inhaled corticosteroids increased significantly over time (p < 0.001) from 13.2% in 1987 to 41.4% in 1995. The percentage of patients receiving oral theophylline decreased significantly (p < 0.001) over this same time interval (63.4 to 29.0%). In addition, the percentage of patients using oral corticosteroids and the percentage using oral beta-adrenergics decreased moderately (p < 0.05) (30.1 to 16.4% and 11.7 to 4.5%, respectively); the percentage of patients using inhaled anticholinergics increased slowly (p < 0.05) (48.2 to 53.8%). The percentage of patients receiving inhaled beta-adrenergics did not significantly (p > 0.05) change.The observed changes in use of inhaled corticosteroids and theophylline were not likely related to differences in disease severity or other patient characteristics in the evaluated trials, but related to changing prescribing and COPD management practices.